(Reuters) – Sanofi announced on Thursday its ambition to become a champion of immunology thanks to recent or upcoming launches of pharmaceutical assets which should generate more than 10 billion euros in annual sales by 2030.

“We are confident in our current product portfolio and the strength of our pipeline to achieve sustainable growth through 2030 and beyond,” Sanofi Chief Executive Officer Paul Hudson said in a statement.

The group indicated that it has 12 potential “blockbusters” currently under clinical study: nine innovative drugs and vaccines with a potential turnover of 2 to 5 billion euros each at cruising speed and 3 assets with potential multiple indications with a potential turnover of more than 5 billion euros each at cruising speed.

The drugmaker said its best-selling anti-inflammatory, Dupixent, is expected to continue to perform strongly and its compound annual revenue growth rate is expected to remain in the low double-digit range between 2023 and 2030.

“Today we occupy a privileged position thanks to many very promising assets at the intermediate or advanced stage of development,” said Houman Ashrafian, head of Research and Development at Sanofi.

“We are confident in our ability to improve clinical outcomes for the benefit of patients everywhere, while bringing innovative new medicines to market and strengthening our leadership in immunology and neuroinflammation.”

The company reiterated its ambition to generate an annual turnover of more than 10 billion euros for its Vaccines activity by 2030.

Sanofi stock has underperformed its rivals in recent years as investors feared the group was too dependent on Dupixent.

(Reporting Anirudh Saligrama and Shivani Tanna in Bangalore; Camille Raynaud)

Copyright © 2023 Thomson Reuters